• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    /C O R R E C T I O N -- National Association of Corporate Directors/

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials
    Get the next $BIIB alert in real time by email

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows:

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence

    WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately.

    The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape.

    Mantas serves on the boards of Biogen (NASDAQ:BIIB), where he chairs the compensation and management development committee, and International Flavors & Fragrances (NYSE:IFF), where he is on the innovation and audit committees. He is a Senior Advisor for NASDAQ, the Council for Global Competition and Innovation and IE University New York College and is vice chair of the board of HITEC. Mantas recently retired as the global leader of IBM Business Transformation Services.

    "I am honored to follow my mentor and fellow IBM senior leader Nick Donofrio as I join the NACD board," Mantas said. "As directors, we face compounding geopolitical, generational and technological disruption in the companies and communities we serve. I look forward to working with the NACD board and the broader corporate governance ecosystem to steward sustainable value creation in the global boardrooms we serve."

    Bricker brings together the combined impact of 134,000 Assurance partners and staff across the PwC network. He helps guide the development of trust, transparency and value creation for companies and investors through innovative, high-quality assurance solutions. Previously, he served as PwC U.S. vice chair and Trust Solutions co-leader, leading the firm's audit, digital assurance and tax reporting practices. Earlier, Bricker was chief accountant of the U.S. Securities and Exchange Commission. He also serves on the board of the American Institute of Certified Professional Accountants (AICPA) and as chair of the board of XBRL International.

    "NACD plays a critical role in elevating board performance and advancing trust in the capital markets," Bricker said. "I'm honored to join the NACD board and contribute to its work in strengthening governance, transparency and board-management alignment."

    Peter Gleason, president and CEO of NACD, welcomed both leaders to the board.

    "Jesús and Wes each bring exceptional insight and experience that reflect the dynamic needs of today's boards," Gleason said. "Jesús' expertise in digital transformation and innovation, combined with Wes' deep understanding of regulatory, legal and audit issues, will be invaluable as NACD continues to equip boards to lead with purpose and confidence."

    Mantas holds degrees in telecommunications and business administration from the Universidad Politécnica de Madrid and has served as an adjunct professor at the University of California Graduate School of Management and is certified in Corporate Governance by Harvard Business School. Bricker is a certified public accountant licensed in Virginia, Pennsylvania, New Jersey and the District of Columbia, and is a member of the New York State Bar Association.

    Visit the NACD Governance web page to learn more. 

    About NACD

    The National Association of Corporate Directors® (NACD®) is the leading member organization for corporate directors who want to expand their knowledge, grow their network and maximize their potential. For more than 47 years, NACD has helped boards and the business community elevate their performance and create long-term value. Our leadership continues to raise standards of excellence and advance board effectiveness at thousands of member companies.

    NACD's value insights, professional development events and resources, such as the NACD Directors Summit™ and the NACD Directorship Certification® program, support boards in navigating complex challenges. With a growing network of more than 24,000 members across more than 20 Chapters, boards are better equipped to make well-informed decisions on the critical, strategic issues facing their businesses today. Learn more at www.nacdonline.org.

    Press Contact: 

    Shannon Bernauer 

    [email protected]

    571-367-3688

    (PRNewsfoto/National Association of Corporate Directors)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/global-leaders-jesus-mantas-and-wes-bricker-join-nacd-board-of-directors-302580855.html

    SOURCE National Association of Corporate Directors

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $IFF

    CompanyDatePrice TargetRatingAnalyst
    Biogen Inc.
    $BIIB
    2/20/2026$185.00Equal Weight
    Barclays
    International Flavors & Fragrances Inc.
    $IFF
    2/13/2026$97.00Perform → Outperform
    Oppenheimer
    Biogen Inc.
    $BIIB
    2/9/2026$194.00 → $228.00Buy
    H.C. Wainwright
    Biogen Inc.
    $BIIB
    1/7/2026$185.00Neutral
    UBS
    Biogen Inc.
    $BIIB
    12/10/2025$143.00Hold → Reduce
    HSBC Securities
    Biogen Inc.
    $BIIB
    11/6/2025$202.00Hold → Buy
    Stifel
    Biogen Inc.
    $BIIB
    9/25/2025$190.00Buy
    Jefferies
    International Flavors & Fragrances Inc.
    $IFF
    9/8/2025Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $BIIB
    $IFF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

    3/25/24 4:41:37 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    SEC Filings

    View All

    SEC Form DEF 14A filed by International Flavors & Fragrances Inc.

    DEF 14A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    3/18/26 8:00:42 AM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form DEFA14A filed by International Flavors & Fragrances Inc.

    DEFA14A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    3/18/26 8:01:20 AM ET
    $IFF
    Major Chemicals
    Industrials

    Biogen Inc. filed SEC Form 8-K: Leadership Update

    8-K - BIOGEN INC. (0000875045) (Filer)

    3/11/26 5:28:01 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $10,971,329 worth of shares (156,459 units at $70.12) and sold $14,481 worth of shares (222 units at $65.23), increasing direct ownership by 92% to 29,650 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $995,204 worth of shares (14,260 units at $69.79), increasing direct ownership by 18% to 91,630 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:47 PM ET
    $IFF
    Major Chemicals
    Industrials

    Head of Pharm Ops and Tech Murphy Nicole bought $585 worth of shares (3 units at $195.03), increasing direct ownership by 0.02% to 19,611 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:16:40 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $10,971,329 worth of shares (156,459 units at $70.12) and sold $14,481 worth of shares (222 units at $65.23), increasing direct ownership by 92% to 29,650 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $995,204 worth of shares (14,260 units at $69.79), increasing direct ownership by 18% to 91,630 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:47 PM ET
    $IFF
    Major Chemicals
    Industrials

    Amendment: New insider Fribourg Paul J claimed ownership of 422 shares (SEC Form 3)

    3/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:46 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

    TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI®), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. The analysis was presented at the 20th International Conference on Alzheimer's an

    3/20/26 12:05:00 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

    Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designationCLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaki

    3/19/26 7:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

    New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapySalanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosingBiogen also debuted the design of the Phase 3 salanersen clinical trial program which is being initiated at sites around the world CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) presented additional results from the Phase 1b study of salanersen, an investigational novel antisense oligonucleotide (ASO) given once a year for spinal muscular

    3/11/26 8:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Biogen with a new price target

    Barclays initiated coverage of Biogen with a rating of Equal Weight and set a new price target of $185.00

    2/20/26 8:23:55 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intl Flavors upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Intl Flavors from Perform to Outperform and set a new price target of $97.00

    2/13/26 7:54:07 AM ET
    $IFF
    Major Chemicals
    Industrials

    H.C. Wainwright reiterated coverage on Biogen with a new price target

    H.C. Wainwright reiterated coverage of Biogen with a rating of Buy and set a new price target of $228.00 from $194.00 previously

    2/9/26 6:43:59 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Leadership Updates

    Live Leadership Updates

    View All

    Mativ Announces Appointment of Seasoned Executive to Its Board of Directors

    Deborah Borg Brings 25+ Years of Corporate Leadership to Global Manufacturing Leader Mativ Holdings, Inc. (NYSE:MATV) announced today the appointment of Deborah Borg to its Board of Directors, effective immediately. In her role on the Mativ Board of Directors, Borg will serve on the Company's Compensation Committee and Nominating & Governance Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124104625/en/Deborah Borg, Mativ Board of Directors Borg is currently the Executive Vice President, Chief People & Culture Officer at International Flavors & Fragrances Inc. (NYSE:IFF), a global leader in food, beverage, health, b

    11/24/25 4:05:00 PM ET
    $IFF
    $MATV
    $SWM
    Major Chemicals
    Industrials
    Paper
    Basic Materials

    IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/Brett Icahn (Photo: IFF) These appointments follow the company's previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Her

    10/22/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Financials

    Live finance-specific insights

    View All

    IFF Declares Dividend for First Quarter 2026

    IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 10, 2026 to shareholders of record as of March 20, 2026. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights

    3/4/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    IFF Reports Fourth Quarter and Full Year 2025 Results

    Delivered solid top and bottom-line performance & advanced strategic priorities in 2025 Launched sale process for the Food Ingredients segment Continuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE:IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Reported   Adjusted (GAAP) (Non-GAAP)1 Sales   Loss Before Taxes   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $10.9 B   $(412) M   $(1.46)   $2.1 B

    2/11/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 2026

    IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2025 earnings results following the market close on Wednesday, Feb. 11, 2026. The management team will host a live webcast on Thursday, Feb. 12, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company's management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 19, 2026 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay

    1/21/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials